Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi

Frontiers in Oncology - Switzerland
doi 10.3389/fonc.2018.00092
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Frontiers Media SA

Related search

Toward Isozyme-Selective Inhibitors of Histone Deacetylase as Therapeutic Agents for the Treatment of Cancer

Pharmaceutical patent analyst
MedicineDrug DiscoveryPharmaceutical Science
2012English

Histone Deacetylase Inhibitors in Cancer Therapy

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2009English

Histone Deacetylase Inhibitors Enhance the Therapeutic Potential of Reovirus in Multiple Myeloma

Molecular Cancer Therapeutics
Cancer ResearchOncology
2016English

Histone Deacetylase Inhibitors as Therapeutic Agents for Cancer Therapy: Drug Metabolism and Pharmacokinetic Properties

2011English

Therapeutic Strategies to Enhance the Anticancer Efficacy of Histone Deacetylase Inhibitors

Journal of Biomedicine and Biotechnology
2011English

New Insights Into the Treatment of Multiple Myeloma With Histone Deacetylase Inhibitors

Current Pharmaceutical Design
Drug DiscoveryPharmacology
2012English

Synthesis of a New Pyridine Pharmaceutical Intermediate in Potential Anti-Cancer of HDACI

DEStech Transactions on Engineering and Technology Research
2017English

Histone Deacetylase Inhibitors as Cancer Therapeutics

Annals of Translational Medicine
Medicine
2016English

Inhibitors of Histone-Deacetylase

Journal of Applied Biomedicine
GeneticsMolecular BiologyPharmacologyBiochemistryBiological SciencesToxicologyMedicineAgriculturalNeurosciencePharmaceutics
2005English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy